JUPITER NEUROSCIENCES, INC.
corporate_fare Company Profile
JUPITER NEUROSCIENCES, INC. (NASDAQ:JUNS) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 41 items for JUNS at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-10-06, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 15 rated 8 or above. Recent SEC coverage for JUNS spans 8-K, 424B5, 10-Q, 424B3.
Recent high-impact activity:
- First Patient Dosed in Phase 2a Parkinson's Trial; Strategic Review Launched
- Nasdaq Moves to Delist Jupiter Neurosciences After $35M Market Value Miss
- Nasdaq Moves to Delist Jupiter Neurosciences; Company to Appeal
- Jupiter Neurosciences Raises $2M at $6.50/Share, Aims to Regain Nasdaq Compliance
- Jupiter Neurosciences Prices $2M Offering and Draws $851K More from Yorkville SEPA
Financial Snapshot
Short Interest & Short Volume
1.00 days to coverFINRA reported short interest of 38,578 shares in JUNS as of the October 15, 2026 settlement, a 8.9% increase from the prior period — about 1.0 days to cover at its recent average daily volume. On November 2, 2026, 27.1% of JUNS volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
High riskFiling-implied dilution signals for JUNS, detected from its recent SEC filings · based on capital-structure filings through 2026-08-24.
Registered Direct Offering Priced · Dilution Impact
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →